KR102376242B1 - 세포 - Google Patents

세포 Download PDF

Info

Publication number
KR102376242B1
KR102376242B1 KR1020217024458A KR20217024458A KR102376242B1 KR 102376242 B1 KR102376242 B1 KR 102376242B1 KR 1020217024458 A KR1020217024458 A KR 1020217024458A KR 20217024458 A KR20217024458 A KR 20217024458A KR 102376242 B1 KR102376242 B1 KR 102376242B1
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
thr
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217024458A
Other languages
English (en)
Korean (ko)
Other versions
KR20210098556A (ko
Inventor
마틴 풀레
숀 코르도바
시모비 오누오하
시몬 토마스
Original Assignee
오토러스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55066668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102376242(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오토러스 리미티드 filed Critical 오토러스 리미티드
Publication of KR20210098556A publication Critical patent/KR20210098556A/ko
Application granted granted Critical
Publication of KR102376242B1 publication Critical patent/KR102376242B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
KR1020217024458A 2014-12-24 2015-12-23 세포 Active KR102376242B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB201423172 2014-12-24
GB1423172.4 2014-12-24
PCT/GB2015/054137 WO2016102965A1 (en) 2014-12-24 2015-12-23 Cell
KR1020197038792A KR20200003939A (ko) 2014-12-24 2015-12-23 세포

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038792A Division KR20200003939A (ko) 2014-12-24 2015-12-23 세포

Publications (2)

Publication Number Publication Date
KR20210098556A KR20210098556A (ko) 2021-08-10
KR102376242B1 true KR102376242B1 (ko) 2022-03-21

Family

ID=55066668

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020177019393A Active KR102085349B1 (ko) 2014-12-24 2015-12-23 세포
KR1020227031979A Ceased KR20220129684A (ko) 2014-12-24 2015-12-23 세포
KR1020197038792A Ceased KR20200003939A (ko) 2014-12-24 2015-12-23 세포
KR1020217024459A Active KR102376244B1 (ko) 2014-12-24 2015-12-23 세포
KR1020237036909A Pending KR20230152824A (ko) 2014-12-24 2015-12-23 세포
KR1020217024458A Active KR102376242B1 (ko) 2014-12-24 2015-12-23 세포

Family Applications Before (5)

Application Number Title Priority Date Filing Date
KR1020177019393A Active KR102085349B1 (ko) 2014-12-24 2015-12-23 세포
KR1020227031979A Ceased KR20220129684A (ko) 2014-12-24 2015-12-23 세포
KR1020197038792A Ceased KR20200003939A (ko) 2014-12-24 2015-12-23 세포
KR1020217024459A Active KR102376244B1 (ko) 2014-12-24 2015-12-23 세포
KR1020237036909A Pending KR20230152824A (ko) 2014-12-24 2015-12-23 세포

Country Status (26)

Country Link
US (8) US11091532B2 (enExample)
EP (3) EP4368704A3 (enExample)
JP (5) JP6633081B2 (enExample)
KR (6) KR102085349B1 (enExample)
CN (2) CN107002045B (enExample)
AU (5) AU2015370679C1 (enExample)
BR (1) BR112017013690A2 (enExample)
CA (2) CA2970440A1 (enExample)
CL (3) CL2017001314A1 (enExample)
DK (2) DK3560953T5 (enExample)
ES (2) ES2976197T3 (enExample)
FI (1) FI3560953T3 (enExample)
HR (1) HRP20240357T1 (enExample)
HU (2) HUE066020T2 (enExample)
IL (4) IL274903B (enExample)
LT (1) LT3560953T (enExample)
MX (1) MX2017006233A (enExample)
PL (2) PL3560953T3 (enExample)
PT (2) PT3560953T (enExample)
RS (1) RS65343B1 (enExample)
RU (2) RU2768019C2 (enExample)
SG (2) SG11201704084VA (enExample)
SI (1) SI3560953T1 (enExample)
SM (1) SMT202400134T1 (enExample)
WO (1) WO2016102965A1 (enExample)
ZA (1) ZA201703381B (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
PT3560953T (pt) 2014-12-24 2024-03-26 Autolus Ltd Célula
PL3253865T3 (pl) 2015-02-06 2022-10-10 National University Of Singapore Sposoby wzmacniania skuteczności terapeutycznych komórek odpornościowych
SG10201908203SA (en) 2015-03-05 2019-10-30 Hutchinson Fred Cancer Res Immunomodulatory Fusion Proteins And Uses Thereof
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
PT3280729T (pt) 2015-04-08 2022-08-01 Novartis Ag Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
TW202444897A (zh) 2015-06-25 2024-11-16 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
CA3029197A1 (en) * 2016-06-24 2017-12-28 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
EP4282969A3 (en) * 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
JP7778468B2 (ja) 2016-11-22 2025-12-02 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断
BR112019011277A2 (pt) 2016-12-02 2019-10-22 University Of Southern California polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
JP2020503015A (ja) * 2016-12-13 2020-01-30 カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 抗ｃｄ１９のヒト化抗体及びｃｄ１９を標的とする免疫エフェクター細胞
EP3567049A4 (en) * 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
US12473343B2 (en) 2017-01-10 2025-11-18 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
WO2018170475A1 (en) 2017-03-17 2018-09-20 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
JP7505885B2 (ja) 2017-04-14 2024-06-25 ザ ジェネラル ホスピタル コーポレイション 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞
US20200048618A1 (en) * 2017-04-18 2020-02-13 Autolus Limited Cell
CN110753555A (zh) 2017-04-19 2020-02-04 得克萨斯州大学系统董事会 表达工程化抗原受体的免疫细胞
US11980640B2 (en) 2017-05-15 2024-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
WO2018237022A1 (en) 2017-06-21 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
JP2020530993A (ja) * 2017-08-02 2020-11-05 オートラス リミテッド キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
SG11202000402PA (en) 2017-08-10 2020-02-27 Nat Univ Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
CN109385402A (zh) * 2017-08-11 2019-02-26 上海恒润达生生物科技有限公司 一种等比例混合两种靶点cart细胞的制备方法及应用
CN107446937B (zh) * 2017-09-05 2020-12-25 深圳华云生物技术有限公司 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用
JP7654240B2 (ja) 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
JP7275118B2 (ja) 2017-10-16 2023-05-17 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ２２免疫療法によってがんを処置するための組成物および方法
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN109988242A (zh) * 2018-01-02 2019-07-09 武汉波睿达生物科技有限公司 联合嵌合抗原受体、表达载体、慢病毒及t细胞
CN108101994B (zh) * 2018-01-04 2020-09-15 广东万海细胞生物科技有限公司 抗cd19抗体及其应用
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
JP7774961B2 (ja) 2018-02-06 2025-11-25 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
JP2021512635A (ja) * 2018-02-12 2021-05-20 ザ ジェネラル ホスピタル コーポレイション 腫瘍微小環境を標的とするキメラ抗原受容体
CN110157738B (zh) * 2018-02-13 2023-06-27 亘喜生物科技（上海）有限公司 靶向cd19和cd22的工程化免疫细胞及其应用
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CN112119096B (zh) * 2018-05-15 2024-04-30 奥托路斯有限公司 嵌合抗原受体
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
AU2019275076B2 (en) 2018-05-23 2024-12-19 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
WO2020011247A1 (en) * 2018-07-13 2020-01-16 Nanjing Legend Biotech Co., Ltd. Co-receptor systems for treating infectious diseases
MX2021003636A (es) 2018-09-27 2021-07-21 Autolus Ltd Receptor antigenico quimerico.
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
GB201820547D0 (en) * 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
CN113543792A (zh) * 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
KR20220010722A (ko) * 2019-05-16 2022-01-26 난징 레전드 바이오테크 씨오., 엘티디. Cd4 결합 모이어티를 포함하는 면역 세포 수용체
AU2020286471B2 (en) * 2019-06-07 2025-07-31 The Trustees Of The University Of Pennsylvania Dual CAR expressing T cells individually linked to CD28 and 4-1BB
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
US20220257757A1 (en) 2019-07-16 2022-08-18 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
AU2020325315A1 (en) 2019-08-07 2022-03-24 Aqualung Therapeutics Corp. Anti-NAMPT antibodies and uses thereof
CN112390891B (zh) * 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 嵌合抗原受体及其构建方法和应用
CN110903401A (zh) * 2019-11-20 2020-03-24 浙江大学 一种靶向cd19的二代嵌合抗原受体及其表达载体与应用
PH12022551291A1 (en) * 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
PH12022551290A1 (en) * 2019-11-26 2023-11-29 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
US20230172981A1 (en) * 2020-02-04 2023-06-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
WO2021180890A1 (en) * 2020-03-11 2021-09-16 Fundació Institut De Recerca Contra La Leucèmia Josep Carreras Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
JP2023530919A (ja) 2020-06-17 2023-07-20 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の製造のための材料及び方法
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
AU2021333653A1 (en) * 2020-08-25 2023-03-23 Cytoimmune Therapeutics, Inc. Bispecific antibody car cell immunotherapy
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN112481284B (zh) * 2020-12-07 2023-07-25 深圳瑞吉生物科技有限公司 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
KR102393776B1 (ko) 2020-12-30 2022-05-04 (주)이노베이션바이오 Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
WO2023016554A1 (zh) * 2021-08-13 2023-02-16 上海医药集团股份有限公司 靶向cd22的抗原结合蛋白及其用途
KR102829757B1 (ko) * 2021-11-17 2025-07-09 (주)이노베이션바이오 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체
EP4522204A1 (en) 2022-05-11 2025-03-19 Autolus Limited Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
EP4558151A1 (en) 2022-07-22 2025-05-28 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
US20240197780A1 (en) * 2022-12-19 2024-06-20 Development Center For Biotechnology Chimeric antigen receptors, nucleic acids encoding the same, and uses thereof in treating cancers
WO2024196796A1 (en) * 2023-03-17 2024-09-26 Cartesian Therapeutics, Inc. Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors
CN121219004A (zh) 2023-05-30 2025-12-26 奥托路斯有限公司 复发性/难治性b细胞急性成淋巴细胞性白血病的cd19car t细胞治疗
WO2024250037A1 (en) * 2023-06-02 2024-12-05 Northeastern University Targeted immune cell therapy utilizing trail and tnf mediated apoptosis
WO2025088308A1 (en) 2023-10-23 2025-05-01 Autolus Limited Products and methods for treating autoimmune diseases
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025215360A1 (en) 2024-04-09 2025-10-16 Autolus Limited Method
WO2025231185A1 (en) 2024-05-01 2025-11-06 Legend Biotech Ireland Limited Viral glycoprotein variants and uses thereof
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
WO2025259108A1 (en) 2024-06-11 2025-12-18 Prinses Máxima Centrum Voor Kinderoncologie B.V. Brain organoid

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2299011A1 (fr) 1975-01-29 1976-08-27 Obert Jean Claude Generateur d'aerosols de part
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
US7052906B1 (en) 1999-04-16 2006-05-30 Celltech R & D Limited Synthetic transmembrane components
JP5312721B2 (ja) * 2000-11-07 2013-10-09 シティ・オブ・ホープ Ｃｄ１９特異的再指向免疫細胞
WO2004106381A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
PT1976886E (pt) 2005-12-16 2015-03-09 Amgen Res Munich Gmbh Meios e processos para o tratamento de doenças tumorais
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
BR112014008849A2 (pt) * 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN103483452B (zh) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
CA2876730A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
KR102198058B1 (ko) * 2012-10-02 2021-01-06 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
US10117896B2 (en) * 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
AU2013335180B2 (en) 2012-10-24 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
KR102417657B1 (ko) * 2013-02-06 2022-07-07 안트로제네시스 코포레이션 개선된 특이성을 갖는 변경된 t 림프구
WO2014138704A1 (en) 2013-03-07 2014-09-12 Baylor College Of Medicine Targeting cd138 in cancer
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
CA2904265C (en) 2013-03-15 2023-08-08 Victor D. FEDOROV Compositions and methods for immunotherapy
RU2727447C2 (ru) 2013-05-13 2020-07-21 Селлектис Cd19-специфический химерный антигенный рецептор и его применения
WO2015010096A1 (en) 2013-07-18 2015-01-22 Baylor College Of Medicine Method of enhancing potency of immune cells
EP3071222B1 (en) * 2013-11-21 2020-10-21 UCL Business Ltd Cell
JP2017504601A (ja) 2013-12-20 2017-02-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法
PT3560953T (pt) 2014-12-24 2024-03-26 Autolus Ltd Célula
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201507111D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
TW202444897A (zh) 2015-06-25 2024-11-16 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
GB201518816D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
GB201610515D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Cell
CN112119096B (zh) 2018-05-15 2024-04-30 奥托路斯有限公司 嵌合抗原受体
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Immunological Methods 1996, 196:51-62.*
PLoS ONE 2013, 8(3): e57838.*

Also Published As

Publication number Publication date
EP3237442B1 (en) 2019-07-10
AU2015370679C1 (en) 2020-09-10
SI3560953T1 (sl) 2024-05-31
AU2022205170A1 (en) 2022-09-15
WO2016102965A1 (en) 2016-06-30
RU2017121892A3 (enExample) 2019-05-28
RU2768019C2 (ru) 2022-03-23
US20200181232A1 (en) 2020-06-11
JP6909844B2 (ja) 2021-07-28
SMT202400134T1 (it) 2024-05-14
US11091532B2 (en) 2021-08-17
DK3560953T5 (da) 2024-09-02
EP3560953A1 (en) 2019-10-30
KR102085349B1 (ko) 2020-03-06
CN114107212A (zh) 2022-03-01
SG10202111107RA (en) 2021-11-29
AU2022205169A1 (en) 2022-09-15
HRP20240357T1 (hr) 2024-06-07
EP3560953B1 (en) 2024-01-31
LT3560953T (lt) 2024-05-10
HUE066020T2 (hu) 2024-07-28
CL2017001314A1 (es) 2017-12-15
KR20200003939A (ko) 2020-01-10
CA2970440A1 (en) 2016-06-30
IL252208B (en) 2021-10-31
IL301458A (en) 2023-05-01
CL2018003216A1 (es) 2019-02-01
IL292508B1 (en) 2023-04-01
EP3237442A1 (en) 2017-11-01
KR20210098556A (ko) 2021-08-10
KR20170092695A (ko) 2017-08-11
US10981970B2 (en) 2021-04-20
US12398194B2 (en) 2025-08-26
DK3237442T3 (da) 2019-09-23
DK3560953T3 (da) 2024-04-02
CN107002045A (zh) 2017-08-01
AU2024278248A1 (en) 2025-01-30
AU2015370679A1 (en) 2017-06-01
US20170340704A1 (en) 2017-11-30
JP2020022508A (ja) 2020-02-13
ZA201703381B (en) 2018-08-29
PL3237442T3 (pl) 2020-02-28
ES2976197T3 (es) 2024-07-26
CA3224507A1 (en) 2016-06-30
RS65343B1 (sr) 2024-04-30
PT3560953T (pt) 2024-03-26
JP2024055976A (ja) 2024-04-19
AU2022205170B2 (en) 2025-02-27
JP2021036913A (ja) 2021-03-11
JP2018501794A (ja) 2018-01-25
US10174099B2 (en) 2019-01-08
MX2017006233A (es) 2017-10-24
RU2022102250A (ru) 2022-03-23
US20180371054A1 (en) 2018-12-27
EP4368704A3 (en) 2024-05-29
KR102376244B1 (ko) 2022-03-21
JP7514746B2 (ja) 2024-07-11
US10098926B2 (en) 2018-10-16
KR20210098557A (ko) 2021-08-10
ES2744910T3 (es) 2020-02-26
NZ731778A (en) 2024-02-23
PT3237442T (pt) 2019-09-26
AU2022205169B2 (en) 2024-09-26
AU2020213352A1 (en) 2020-08-27
IL274903A (en) 2020-07-30
EP4368704A2 (en) 2024-05-15
BR112017013690A2 (pt) 2018-03-06
US20250353893A1 (en) 2025-11-20
HUE046262T2 (hu) 2020-02-28
IL274903B (en) 2022-07-01
KR20220129684A (ko) 2022-09-23
IL292508A (en) 2022-06-01
JP2022002546A (ja) 2022-01-11
FI3560953T3 (fi) 2024-03-21
US11034750B2 (en) 2021-06-15
AU2020213352B2 (en) 2022-08-18
AU2015370679B2 (en) 2020-05-21
IL252208A0 (en) 2017-07-31
KR20230152824A (ko) 2023-11-03
IL292508B2 (en) 2023-08-01
US20170340705A1 (en) 2017-11-30
SG11201704084VA (en) 2017-06-29
RU2017121892A (ru) 2019-01-24
PL3560953T3 (pl) 2024-05-13
CL2018003217A1 (es) 2019-02-01
CN107002045B (zh) 2025-10-21
US20190161531A1 (en) 2019-05-30
US20230331810A1 (en) 2023-10-19
US20170369550A1 (en) 2017-12-28
JP6633081B2 (ja) 2020-01-22

Similar Documents

Publication Publication Date Title
AU2022205170B2 (en) Chimeric Antigen Receptor
CN118440211A (zh) 嵌合抗原受体
KR20210066865A (ko) 키메라 항원 수용체
CN115551544A (zh) 细胞
HK1243425B (en) Cell
HK1243425A1 (en) Cell

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210802

Application number text: 1020197038792

Filing date: 20191230

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210826

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211111

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220221

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220315

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220316

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250313

Start annual number: 4

End annual number: 4